Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (341-350 of 493) with videos related to

Pageof 50
Sort By:
European Urology|February 11, 2011
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinomaKatherine M Krajewski, Mengye Guo, Annick D Van den Abbeele, et al.
Frontiers in Oncology|December 6, 2024
Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiationKelly Gaudian, Min Jung Koh, Min Ji Koh, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.
Melanoma Research|September 1, 2018
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patientsSally Y Tan, Julie Najita, Xiaoxue Li, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Oncotarget|September 11, 2020
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastasesGino K In, Kelsey Poorman, Michelle Saul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint InhibitorsAnita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancerHans J van der Vliet, Hans J J van der Vliet, Henry B Koon, et al.
Pageof 50

Showing results (341-350 of 493) with videos related to

Sort By:
Pageof 50
European Urology|February 11, 2011
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinomaKatherine M Krajewski, Mengye Guo, Annick D Van den Abbeele, et al.
Frontiers in Oncology|December 6, 2024
Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiationKelly Gaudian, Min Jung Koh, Min Ji Koh, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.
Melanoma Research|September 1, 2018
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patientsSally Y Tan, Julie Najita, Xiaoxue Li, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Oncotarget|September 11, 2020
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastasesGino K In, Kelsey Poorman, Michelle Saul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint InhibitorsAnita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancerHans J van der Vliet, Hans J J van der Vliet, Henry B Koon, et al.
Pageof 50